AR098616A1 - Péptido para el tratamiento de hipoglicemia severa - Google Patents
Péptido para el tratamiento de hipoglicemia severaInfo
- Publication number
- AR098616A1 AR098616A1 ARP140104514A ARP140104514A AR098616A1 AR 098616 A1 AR098616 A1 AR 098616A1 AR P140104514 A ARP140104514 A AR P140104514A AR P140104514 A ARP140104514 A AR P140104514A AR 098616 A1 AR098616 A1 AR 098616A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- peptide
- glu
- leu
- lys
- Prior art date
Links
- 208000013016 Hypoglycemia Diseases 0.000 title abstract 2
- 230000002218 hypoglycaemic effect Effects 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Removal Of Specific Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente se refiere a un péptido útil en el tratamiento de hipoglicemia. Reivindicación 1: Un compuesto caracterizado porque comprende la secuencia de aminoácido de Tyr-Ser-His-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Lys-Tyr-Leu-Asp-(Aib)-Lys-Lys-Ala-Ala-Glu-Phe-Val-Ala-Trp-Leu-Leu-Glu-Glu (SEC ID Nº 2).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361917658P | 2013-12-18 | 2013-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098616A1 true AR098616A1 (es) | 2016-06-01 |
Family
ID=52278803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104514A AR098616A1 (es) | 2013-12-18 | 2014-12-04 | Péptido para el tratamiento de hipoglicemia severa |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9688736B2 (es) |
| EP (1) | EP3083669A1 (es) |
| JP (1) | JP2017503782A (es) |
| KR (1) | KR20160077215A (es) |
| CN (1) | CN105793282A (es) |
| AP (1) | AP2016009268A0 (es) |
| AR (1) | AR098616A1 (es) |
| AU (1) | AU2014366427B2 (es) |
| BR (1) | BR112016012505A2 (es) |
| CA (1) | CA2928987A1 (es) |
| CL (1) | CL2016001473A1 (es) |
| CR (1) | CR20160223A (es) |
| DO (1) | DOP2016000128A (es) |
| EA (1) | EA201691036A1 (es) |
| EC (1) | ECSP16024805A (es) |
| HK (1) | HK1224303A1 (es) |
| IL (1) | IL245399A0 (es) |
| MA (1) | MA39108A1 (es) |
| MX (1) | MX2016007984A (es) |
| NZ (1) | NZ719451A (es) |
| PE (1) | PE20160787A1 (es) |
| PH (1) | PH12016501184A1 (es) |
| SG (1) | SG11201604232TA (es) |
| TN (1) | TN2016000180A1 (es) |
| TW (1) | TW201609129A (es) |
| WO (1) | WO2015094878A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| WO2019140024A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| JP7212171B2 (ja) | 2019-02-05 | 2023-01-24 | イーライ リリー アンド カンパニー | グルカゴン類似体アゴニストおよびその使用方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2674354A1 (en) | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| CA2713348C (en) | 2008-01-30 | 2018-10-09 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| TWI474832B (zh) | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | 胰高血糖素／ｇｌｐ-１受體共同激動劑 |
| EP2307037A4 (en) | 2008-06-17 | 2011-08-03 | Univ Indiana Res & Tech Corp | GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS |
| PE20120332A1 (es) | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
| CN104961822A (zh) | 2009-07-13 | 2015-10-07 | 西兰制药公司 | 酰化胰高血糖素类似物 |
| EA026384B1 (ru) | 2010-01-20 | 2017-04-28 | Зилэнд Фарма А/С | Лечение заболеваний сердца |
| MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
| US20130053310A1 (en) * | 2010-03-26 | 2013-02-28 | Novo Nordisk A/S | Novel glucagon analogues |
| US20130035285A1 (en) * | 2010-03-26 | 2013-02-07 | Novo Nordisk A/S | Novel glucagon analogues |
| JP6121323B2 (ja) | 2010-05-13 | 2017-05-10 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド |
| JP6050746B2 (ja) | 2010-05-13 | 2016-12-21 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド |
| AU2011269430A1 (en) | 2010-06-24 | 2013-01-10 | Zealand Pharma A/S | Glucagon analogues |
| MX2012014576A (es) | 2010-06-24 | 2013-02-21 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida. |
| WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
| NZ611878A (en) | 2010-12-22 | 2015-02-27 | Marcadia Biotech Inc | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| PH12013501495A1 (en) | 2011-01-20 | 2013-09-16 | Zealand Pharma As | Combination of acylated glucagon analogues with insulin analogues |
| CA2830974A1 (en) | 2011-03-28 | 2012-10-04 | Jesper F. Lau | Novel glucagon analogues |
| KR101968344B1 (ko) * | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
-
2014
- 2014-12-04 AR ARP140104514A patent/AR098616A1/es unknown
- 2014-12-05 TW TW103142476A patent/TW201609129A/zh unknown
- 2014-12-11 KR KR1020167015881A patent/KR20160077215A/ko not_active Ceased
- 2014-12-11 MA MA39108A patent/MA39108A1/fr unknown
- 2014-12-11 TN TN2016000180A patent/TN2016000180A1/en unknown
- 2014-12-11 NZ NZ719451A patent/NZ719451A/en not_active IP Right Cessation
- 2014-12-11 WO PCT/US2014/069646 patent/WO2015094878A1/en not_active Ceased
- 2014-12-11 AP AP2016009268A patent/AP2016009268A0/en unknown
- 2014-12-11 MX MX2016007984A patent/MX2016007984A/es unknown
- 2014-12-11 HK HK16112376.1A patent/HK1224303A1/zh unknown
- 2014-12-11 EA EA201691036A patent/EA201691036A1/ru unknown
- 2014-12-11 US US15/103,169 patent/US9688736B2/en not_active Expired - Fee Related
- 2014-12-11 CN CN201480067301.4A patent/CN105793282A/zh active Pending
- 2014-12-11 PE PE2016000823A patent/PE20160787A1/es not_active Application Discontinuation
- 2014-12-11 BR BR112016012505A patent/BR112016012505A2/pt not_active IP Right Cessation
- 2014-12-11 SG SG11201604232TA patent/SG11201604232TA/en unknown
- 2014-12-11 CA CA2928987A patent/CA2928987A1/en not_active Abandoned
- 2014-12-11 EP EP14821986.8A patent/EP3083669A1/en not_active Withdrawn
- 2014-12-11 JP JP2016540652A patent/JP2017503782A/ja not_active Ceased
- 2014-12-11 AU AU2014366427A patent/AU2014366427B2/en not_active Ceased
-
2016
- 2016-05-02 IL IL245399A patent/IL245399A0/en unknown
- 2016-05-16 CR CR20160223A patent/CR20160223A/es unknown
- 2016-06-07 DO DO2016000128A patent/DOP2016000128A/es unknown
- 2016-06-13 CL CL2016001473A patent/CL2016001473A1/es unknown
- 2016-06-16 EC ECIEPI201624805A patent/ECSP16024805A/es unknown
- 2016-06-17 PH PH12016501184A patent/PH12016501184A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015094878A1 (en) | 2015-06-25 |
| US9688736B2 (en) | 2017-06-27 |
| EP3083669A1 (en) | 2016-10-26 |
| BR112016012505A2 (pt) | 2017-09-26 |
| PE20160787A1 (es) | 2016-08-17 |
| HK1224303A1 (zh) | 2017-08-18 |
| IL245399A0 (en) | 2016-06-30 |
| NZ719451A (en) | 2017-10-27 |
| CN105793282A (zh) | 2016-07-20 |
| AP2016009268A0 (en) | 2016-06-30 |
| US20160311883A1 (en) | 2016-10-27 |
| ECSP16024805A (es) | 2017-02-24 |
| TN2016000180A1 (en) | 2017-10-06 |
| CL2016001473A1 (es) | 2017-03-10 |
| TW201609129A (zh) | 2016-03-16 |
| JP2017503782A (ja) | 2017-02-02 |
| EA201691036A1 (ru) | 2016-12-30 |
| CR20160223A (es) | 2016-07-12 |
| AU2014366427A1 (en) | 2016-05-19 |
| PH12016501184A1 (en) | 2016-07-25 |
| DOP2016000128A (es) | 2016-06-30 |
| SG11201604232TA (en) | 2016-07-28 |
| KR20160077215A (ko) | 2016-07-01 |
| CA2928987A1 (en) | 2015-06-25 |
| MA39108A1 (fr) | 2017-11-30 |
| AU2014366427B2 (en) | 2017-02-16 |
| MX2016007984A (es) | 2016-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016001405A1 (es) | A peptide mixture | |
| CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
| CU20160060A7 (es) | Péptidos, ácidos nucleicos y células, útiles en la inmunoterapia personalizada contra diversos tumores cerebrales y neuronales | |
| AR093903A1 (es) | Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad | |
| MX2018012166A (es) | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). | |
| CR20160049A (es) | Bioconjugados de polipéptidos de apelina sintética | |
| MX364777B (es) | Péptidos cancerígenos universales derivados de telomerasa. | |
| AR128395A2 (es) | Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9 | |
| EA201890815A1 (ru) | Аминокислотные композиции с модифицированным высвобождением для перорального введения | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| CU20210061A7 (es) | Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer | |
| SG10201805039UA (en) | Protease resistant peptides | |
| EA201492068A1 (ru) | Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии | |
| AR098615A1 (es) | Péptido para el tratamiento de hipoglicemia severa | |
| PH12015500890A1 (en) | Vaccine for preventing porcine edema disease | |
| CO2019006443A2 (es) | Peptido para tratar degeneracion macular relacionada con la edad | |
| AR098616A1 (es) | Péptido para el tratamiento de hipoglicemia severa | |
| MX2015002279A (es) | Peptido pntx(19) sintético, composición farmacéutica.y uso. | |
| AR083766A1 (es) | Peptido inmunogenico | |
| PE20160877A1 (es) | Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion | |
| PE20160848A1 (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa | |
| ES2526109R2 (es) | Péptido y composición farmacéutica para el tratamiento del cáncer | |
| IN2014MN01376A (es) | ||
| MX376994B (es) | Péptido c-terminal de acetilcolinesterasa cíclico para usarse en el tratamiento o la prevención de cáncer o metástasis. | |
| MX2020005454A (es) | Tratamiento de cancer mejorado. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |